Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1

Summary

The purpose of the study is to evaluate the effect of a single, acute dose of BNC210 compared to placebo on reducing the severity of anxiety provoked by a behavioral assessment task and measured using the Subjective Units of Distress Scale (SUDS) in adult patients with social anxiety disorder.

Timeline

Start

2024-08-06

Primary completion

2025-09-11

Completion

2025-09-19

Outcome

Missed primary endpoint

release “AFFIRM -1 Phase 3 clinical trial on October 20, 2025, in which Neuphoria announced that the trial missed its primary” scancell.co.uk ↗

Drugs

Indications